About
Gene Editing
Areas of Focus
Categories
Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide TherapyBiotech
Team (23)
Annalisa Jenkins, M.B.B.S., F.R.C.P.
Biopharma & Life Sciences Executive
Excision BioTherapeutics
team_member
Ashok Krishnamurthi
Managing Partner, GreatPoint Ventures
Excision BioTherapeutics
team_member
Barbara Mohl
Head of Human Resources “Consultant”
Excision BioTherapeutics
team_member
Bill Carson, M.D.
Chairman of the Board, Otsuka Pharmaceutical Development & Commercialization, Inc.
Excision BioTherapeutics
board_chair
Daniel Dornbusch, MPH MBA
Chief Executive Officer
Excision BioTherapeutics
executive
Elvin Ruan
Sr. Director, Genome Editing
Excision BioTherapeutics
team_member
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
15
By Phase
PHASE1: 2
By Status
ENROLLING_BY_INVITATION: 1COMPLETED: 1
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
Today
Hover over trial bars to see details
Recent Trials
NCT05143307Lead Sponsor
Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101
PHASE1Enrolling by invitation
9 participants
Started: Jul 11, 2023 · Completed: Apr 30, 2037
NCT05144386Lead Sponsor
Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART
PHASE1Completed
6 participants
Started: Jan 24, 2022 · Completed: Nov 14, 2024
Locations (1)
Headquarters
San Francisco, CA, United States
Map
Loading map...